Latest research on Bumetanide

A sulfamyl diuretic. [PubChem]

Latest findings

Stock solutions of Carbachol, ATP, apyrase (ATP diphosphohydrolase), aprotinin, trypsin, and hexamethonium bromide were made in sterilized deionized water and Bumetanide, an inhibitor of Na+/K+/2Cl− transporter in alkaline solution while benzamil, CFTRinh172, GlyH101, thapsigargin, U73122 (a phospholipase C, PLC, inhibitor), and Atropine were dissolved in Dimethyl sulfoxide (DMSO, Me2SO). [source, 2016]
To further explore a role for anion secretion, we stimulated sheep trachea with Carbachol in normal Krebs-Ringer bicarbonate (KRB) buffer and in a buffer designed to block anion transport (HEPES for replacing HCO3− and 100 μM Bumetanide to block, Na+/K+/2Cl− cotransporter, NKCC). [source, 2016]
No significant difference in carbachol-induced inhibition of the ENaC-dependent Isc was observed when anion transport was reduced by Bumetanide + HEPES (the residual ENaC-dependent ENaC Isc: 11.6 ± 2.7 in KRB and 11.4 ± 2.6 μA/cm2, P = 0.8, n = 6 from 4 sheep), while the transient Isc increase was greatly reduced in HEPES + Bumetanide buffer (14.7 ± 2.4 in KRB and 7.8 ± 2.8 μA/cm2 in HEPES + Bm) (Figure 3). [source, 2016]
Recently, Bumetanide, an inhibitor of the Na-K-2Cl co-transporter was shown to prevent this paradoxical depolarisation in hypokalaemic conditions in animal studies and was also shown to prevent attacks in mouse models of sodium and Calcium channel mutations. [source, 2016]
Clinical trials of Bumetanide for Hypo PP are starting. [source, 2016]
A recent review of loop diuretics in managing nephrotic and other forms of systemic edema indicates several advantages of Bumetanide, including greater bioavailability than Furosemide as well as the convenience of 1:1 intravenous to oral conversion (67). [source, 2016]
When this is combined with Bumetanide and SPA, a brisk diuresis is usually achieved. [source, 2016]
To test if the depolarizing action of GABA in the BLA was due to NKCC1 expression in the AIS, we determined the effect of the NKCC1 antagonist Bumetanide. [source, 2016]
Bumetanide had no effect on the fbEPSP (n = 4; Fig. 5A). [source, 2016]
Bumetanide [0.1–0.2 mg/kg dissolved in 100% alcohol, aliquoted, and stored at −20°C; protocol similar to previous study (Dzhala et al., 2005)], Phenobarbital (25 mg/kg dissolved in 0.9% sodium chloride, made on the day of experiment), or 0.9% sodium chloride was injected intraperitoneally (IP) after baseline post-stroke EEGs were recorded (Figure 1C). [source, 2015]